WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

Core Viewpoint - WuXi Biologics has been recognized for its sustainability efforts by being included in the FTSE4Good Index Series for the fourth consecutive year, highlighting its commitment to Environmental, Social, and Governance (ESG) practices [1][3][6] Group 1: Sustainability Achievements - The company has made significant progress in sustainable development, aligning with the United Nations Sustainable Development Goals, and has received various accolades from ESG rating agencies, including a "AAA" rating from MSCI ESG Ratings and a Platinum Medal from EcoVadis [2][5] - WuXi Biologics' ESG score in 2024 ranked in the top 7% of its industry, reflecting substantial improvements in its overall ESG performance [6] Group 2: Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for the discovery, development, and manufacturing of biologics [4][7] - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore, and is currently supporting 698 integrated client projects, with 24 in commercial manufacturing as of December 31, 2023 [7] Group 3: Leadership and Strategy - The CEO of WuXi Biologics, Dr. Chris Chen, emphasized the company's commitment to sustainability as a cornerstone of business growth and the effectiveness of its comprehensive ESG strategy [3][5] - An ESG committee led by the CEO has been established to guide the implementation of the company's ESG strategy, reinforcing its dedication to sustainability [5]